Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.3 · PDF-Seite 5
HOS-147406 · Präparat HOS-099656
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage 8cc0fe29768569a55e0703c8413d5a145077448bca5f7426ab9084406d167fa6 · Zeichen 0–91 im Abschnitt
Wechselwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 7
HOS-147407 · Präparat HOS-099656
No interaction studies have been performed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage 5983a4f3930ffd7eace002cee506bbd1833a962ab9403b1cddd2966b44151e12 · Zeichen 0–43 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-147408 · Präparat HOS-099656
Summary of the safety profile
Patients with relapsed or refractory DLBCL
The safety of tafasitamab in patients with DLBCL was evaluated in the open-label, multicentre, single-
arm phase 2 study L-MIND in 81 patients with relapsed or refractory DLBCL. Patients received
tafasitamab 12 mg/kg intravenously in combination with lenalidomide for a maximum of 12 cycles,
followed by tafasitamab monotherapy until disease progression or unacceptable toxicity.
The median duration of exposure to tafasitamab was 7.7 months.
The most common adverse reactions were: infections (73%), neutropenia (51%), asthenia (40%),
anaemia (36%), diarrhoea (36%), thrombocytopenia (31%), cough (26%), oedema peripheral (24%),
pyrexia (24%), decreased appetite (22%).
The most common serious adverse reactions were infection (26%) including pneumonia (7%), and
febrile neutropenia (6%).
Permanent discontinuation of tafasitamab due to an adverse reaction occurred in 15% of patients. The
most common adverse reactions leading to permanent discontinuation of tafasitamab were infections
and infestations (5%), nervous system disorders (2.5%), and respiratory, thoracic and mediastinal
disorders (2.5%).
The frequency of dose modification or interruption due to adverse reactions was 65%. The most
common adverse reactions leading to tafasitamab treatment interruption were blood and lymphatic
system disorders (41%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage 93886395ff7cf809db57a944af87f488f2c81f4300d2a801c942224932efd1d4 · Zeichen 0–1391 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-147409 · Präparat HOS-099656
Patients with relapsed or refractory FL after at least one line of systemic therapy
The safety of tafasitamab in patients with FL was evaluated in the randomised, double-blind, placebo-
controlled multicenter phase 3 study inMIND in 652 patients, including 546 participants with relapsed
or refractory (R/R) follicular lymphoma and 106 participants with R/R marginal zone lymphoma.
Patients received tafasitamab 12 mg/kg (n = 327) or placebo (n = 325) intravenously in combination
with rituximab 375 mg/m2 intravenously (for a maximum of 5 cycles) and lenalidomide 20 mg orally
(for a maximum of 12 cycles). Tafasitamab treatment was stopped after 12 cycles. Among patients
who received tafasitamab, 83% were exposed for 6 months or longer. The median duration of
exposure to tafasitamab was 322 days.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage 7c27aa0216df42ce1eb1b1c8f27cacdc67acba3800563c85973af9d47cc708ce · Zeichen 1393–2194 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-147410 · Präparat HOS-099656
In the inMIND study, the most common adverse reactions were infections (68%), including viral
infections (41%) and bacterial infections (27%); neutropenia (57%), rash (36.4%), asthenia (34.9%),
pyrexia (19%), thrombocytopenia (17%), anaemia (17%), infusion related reaction (15.9%), pruritus
(15.6%) and headache (10.4%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage 399a63477d0602c4b84b6c64a759c852ec8e2a48690ad5b07a55f16ac10d3890 · Zeichen 2196–2517 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-147411 · Präparat HOS-099656
The most common serious adverse reactions were infections (26%), including viral infections (13%),
and bacterial infections (6%); febrile neutropenia (2.8%), acute kidney injury (2.8%) and pyrexia
(1.8%).
Permanent discontinuation of tafasitamab due to an adverse reaction occurred in 11.6% of patients.
The most common adverse reactions leading to permanent discontinuation of tafasitamab were viral
infections (2.4%), including COVID-19 (1.5%) and COVID-19 pneumonia (1.2%), infusion-related
reaction (0.9%) and pyrexia (0.9%).
The frequency of tafasitamab dose modification or interruption due to adverse reactions was 74.9%.
The most common adverse reactions leading to tafasitamab dose modification and interruption were
neutropenia (38.8%) and viral infections (23.9%) including COVID-19 (21.1%) and COVID-19
pneumonia (3.7%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage 10cef24afd770bfb0732e3c217d1b127f6200209ab17f6aeeac80c19a78483cf · Zeichen 2519–3351 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-147412 · Präparat HOS-099656
Tabulated list of adverse reactions
Adverse reactions reported for tafasitamab in clinical trials are listed by MedDRA System Organ Class
and by frequency.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage 2a0e9af46897aad473b10a6faf193f3479cec7306a23dec5138b3361af62088a · Zeichen 3353–3508 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-147413 · Präparat HOS-099656
The adverse reaction frequencies from clinical trials are based on all-cause adverse event frequencies,
where a proportion of the events for an adverse reaction may have other causes than the medicinal
product, such as the disease, other medicines or unrelated causes. Frequencies are defined as follows:
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage c5dcc5107b16bf24c90e0c48190f8bc5654b0ab6507d30013252e4713f9b6420 · Zeichen 3510–3814 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8–9
HOS-147414 · Präparat HOS-099656
8
very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare
(≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); and not known (cannot be estimated from the
available data). Within each frequency grouping, adverse reactions are presented in order of
decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage e9385e4e719c23f25a454e12e1b7c21b08980e95c0ee49885d7a1033a9dae130 · Zeichen 3867–4169 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 9
HOS-147415 · Präparat HOS-099656
Table 2: Adverse reactions in patients with relapsed or refractory DLBCL who received
tafasitamab in combination with lenalidomide in the clinical trial MOR208C203
(L-MIND)
System organ class Frequency Adverse reactions
Infections and infestations Very common Bacterial, viral and fungal infections+,
including opportunistic infections with fatal
outcomes (e.g. bronchopulmonary
aspergillosis, bronchitis, pneumonia and
urinary tract infection)
Common Sepsis (including neutropenic sepsis)
Neoplasms benign, Common Basal cell carcinoma
malignant and unspecified
(incl. cysts and polyps)
Blood and lymphatic system Very common Febrile neutropenia+, neutropenia+,
disorders thrombocytopenia+, anaemia, leukopenia+
Common Lymphopenia
Immune system disorders Common Hypogammaglobulinaemia
Metabolism and nutrition Very common Hypokalaemia, decreased appetite
disorders Common Hypocalcaemia, hypomagnesaemia
Nervous system disorders Common Headache, paraesthesia, dysgeusia
Respiratory, thoracic and Very common Dyspnoea, cough
mediastinal disorders Common Exacerbation of chronic obstructive pulmonary
disease, nasal congestion
Gastrointestinal disorders Very common Diarrhoea, constipation, vomiting, nausea,
abdominal pain
Hepatobiliary disorders Common Hyperbilirubinaemia, transaminases increased
(includes ALT and/or AST increased),
Gamma-glutamyltransferase increased
Skin and subcutaneous Very common Rash (includes different types of rash, e.g. rash,
tissue disorders rash maculopapular, rash pruritic, rash
erythematous)
Common Pruritus, alopecia, erythema, hyperhidrosis
Musculoskeletal and Very common Back pain, muscle spasms
connective tissue disorders Common Arthralgia, pain in extremity, musculoskeletal
pain
Renal and urinary disorders Common Blood creatinine increased
General disorders and Very common Asthenia++ , oedema peripheral, pyrexia
administration site Common Mucosal inflammation
conditions
Investigations Common Weight decreased, C-reactive protein increased
Injury, poisoning and Common Infusion related reaction
procedural complications
+Further information on this adverse reaction is provided in the text below.
++ Asthenia includes asthenia, fatigue and malaise.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage 808cd63b9f0a4f5fa9f36f376762bd177e823c57e8ed82745301581ae5b664c2 · Zeichen 4171–7492 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 9
HOS-147416 · Präparat HOS-099656
Compared with the incidences on combination therapy with lenalidomide, the incidences of non-haematological adverse
reactions on tafasitamab monotherapy decreased by at least 10% for decreased appetite, asthenia, hypokalaemia, constipation,
nausea, muscle spasms, dyspnoea and C-reactive protein increased.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage 0e2ddcec52ae1673bb40ce8044c397094f8abe72bd9586cf91f650be3307ebe3 · Zeichen 7494–7800 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 9–10
HOS-147417 · Präparat HOS-099656
9
Table 3: Adverse reactions in patients with relapsed or refractory FL who received tafasitamab
in combination with rituximab and lenalidomide in INCMOR 0208-301 (inMIND)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage 60fc6b864ca95a5006b17f4b20ddc658a84751e5bc70a546d601244a05010c4a · Zeichen 7865–8046 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-147418 · Präparat HOS-099656
System organ class / Adverse All grades Grade 3-4a
reaction frequency frequency
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage a29e8e22803f079248547a7688c786b85d6daef1da31c1863992aed4ef104fdc · Zeichen 8049–8276 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-147419 · Präparat HOS-099656
Infections and infestations
Viral infectionsb Very common Very common
Bacterial infectionsc Very common Common
Pneumonia Very common Common
Bronchitis Common -
Sepsis Common Uncommon
Blood and lymphatic system disorders
Neutropeniad Very common Very common
Thrombocytopeniae Very common Common
f
Anaemia Very common Common
Febrile neutropenia Common Common
Leukopenia Common Uncommon
Metabolism and nutrition disorders
Tumour lysis syndrome Uncommon Uncommon
Nervous system disorders
Headache Very common Uncommon
Gastrointestinal disorders
Diarrhoea Very common Uncommon
Constipation Very common Uncommon
Abdominal paing Very common -
Skin and subcutaneous tissue disorders
Rashh Very common Common
Pruritus Very common Uncommon
General disorders and administration site conditions
Astheniai Very common Common
Pyrexia Very common Common
Chills Common -
Investigations
ALT increased Common Uncommon
AST increased Common Uncommon
Injury, poisoning, and procedural complications
Infusionrelated reaction Very common Uncommon
a The severity of adverse drug reactions was assessed based on the CTCAE, defining grade 1 = mild, grade 2 =
moderate, grade 3 = severe, grade 4=life threatening, and 5=death.
b Includes viral infection, COVID-19, COVID-19 pneumonia, coronavirus infection, coronavirus test positive,
cytomegalovirus chorioretinitis, cytomegalovirus infection reactivation, gastroenteritis rotavirus, genital herpes,
Hepatitis B, herpes ophthalmic, herpes simplex, herpes simplex reactivation, herpes virus infection, herpes zoster,
herpes zoster reactivation, influenza, laryngitis viral, nasal herpes, norovirus infection, oral herpes, parainfluenzae
virus infection, pneumonia viral, progressive multifocal leukoencephalopathy, respiratory syncytial virus infection,
respirovirus test positive, rhinovirus infection, skin papilloma, varicella zoster pneumonia, varicella zoster virus
infection, and viral upper respiratory tract infection.
c Includes bacterial infection, abdominal infection, abscess, appendicitis, asymptomatic bacteriuria, atypical
pneumonia, bacteraemia, bacterial sepsis, breast abscess, bronchopulmonary aspergillosis, campylobacter
gastroenteritis, campylobacter infection, carbuncle, catheter site infection, cellulitis, cholecystitis, chronic sinusitis,
clostridium difficile colitis, clostridium difficile infection, corynebacterium infection, device related infection,
diverticulitis, ear infection, ear lobe infection, empyema, enterobacter bacteraemia, erysipelas, erythrasma,
escherichia infection, escherichia sepsis, eye infection, folliculitis, furuncle, hemophilus bacteraemia, hemophilus
infection, helicobacter gastritis, helicobacter infection, infected cyst, infected dermal cyst, lower respiratory tract
infection, moraxella infection, mycobacterium chelonae infection, myopericarditis, myringitis, otitis externa, otitis
media, perineal infection, periodontitis, peritonitis bacterial, pneumocystis jirovecii pneumonia, pneumonia
moraxella, pneumonia pneumococcal, pneumonia streptococcal, postoperative wound infection, proctitis, prostatitis,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage 49465686f8741349f934d6993f592a2c0e3cc0e53e2de51f81605ecdbb686026 · Zeichen 8279–13355 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10–11
HOS-147420 · Präparat HOS-099656
10
pseudomonal sepsis, pseudomonal skin infection, pseudomonas infection, pulmonary sepsis, pulpitis dental,
pyelonephritis, salmonellosis, septic shock, sinusitis, skin infection, soft tissue infection, staphylococcal bacteraemia,
staphylococcal infection, tooth abscess, tooth infection, urinary tract infection, urosepsis, vaginal infection, and
wound infection.
d Includes neutropenia and neutrophil count decreased.
e Includes thrombocytopenia and platelet count decreased.
f Includes anaemia and haematocrit decreased.
g Includes abdominal pain, abdominal discomfort, abdominal pain lower, abdominal pain upper, and gastrointestinal
pain.
h Includes rash, rash erythematous, rash maculo-papular, rash papular, rash pruritic, rash pustular, rash vesicular, and
urticaria.
i Includes asthenia, malaise, and fatigue.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage 06cda18aa50e1ddd66ef04fe2a6d688818a46a38fb8004f12a535efe1b40d7ff · Zeichen 13420–14288 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-147421 · Präparat HOS-099656
Description of selected adverse reactions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage f66db2a8100a521c1dea72ff90e696fa3846f9d5fcd6cf8e5e03ce5d71bde4a7 · Zeichen 14292–14333 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-147422 · Präparat HOS-099656
Myelosuppression
Treatment with tafasitamab can cause serious or severe myelosuppression including neutropenia,
thrombocytopenia and anaemia (see sections 4.2 and 4.4).
In the L-MIND study, myelosuppression (i.e. neutropenia, febrile neutropenia, thrombocytopenia,
leukopenia, lymphopenia or anaemia) occurred in 65.4% of patients treated with tafasitamab.
Myelosuppression led to interruption of tafasitamab in 41% and to tafasitamab discontinuation in
1.2%.
In the inMIND study, myelosuppression (i.e. neutropenia, febrile neutropenia, thrombocytopenia,
leukopenia, lymphopenia or anaemia) occurred in 63.3% of patients treated with tafasitamab,
lenalidomide, and rituximab (tafasitamab group) and 63.1% of patients treated with lenalidomide and
rituximab (placebo group). Grade 4 haematological adverse reactions included neutropenia,
thrombocytopenia and febrile neutropenia. Myelosuppression led to interruption of tafasitamab in
42.8% and to tafasitamab discontinuation in 1.5%.
Myelosuppression was managed by reduction or interruption of lenalidomide, interruption of
tafasitamab and/or rituximab. In addition, severe neutropenia was managed by the administration of
GCSF (see sections 4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage d16a4a30a7add75ddbc4055270bd27e2a0cd48f36b56aa323b339878b72ffcf0 · Zeichen 14335–15542 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-147423 · Präparat HOS-099656
Neutropenia/febrile neutropenia
In the L-MIND study, incidence of neutropenia was 51%. Incidence of Grade 3 or 4 neutropenia was
49% and of Grade 3 or 4 febrile neutropenia was 12%. Median duration of any adverse reaction of
neutropenia was 8 days (range 1 – 222 days); median time to onset to first occurrence of neutropenia
was 49 days (range 1 – 994 days).
In the inMIND study, incidence of neutropenia was 56.9% in the tafasitamab group (tafasitamab,
lenalidomide and rituximab) and 54.2% in the placebo group (lenalidomide and rituximab). Incidence
of Grade 3 or 4 neutropenia was 46.8% in the tafasitamab group and 45.5% in the placebo group.
Incidence of Grade 3 or Grade 4 febrile neutropenia was 4.3% in the tafasitamab group and 3.4% in
the placebo group. Median duration of any adverse reaction of neutropenia was 11 days (range 1 – 433
days). Median duration of febrile neutropenia was 5 days (range 1 – 57 days); median time to onset to
first occurrence of neutropenia was 57 days (range 1 – 338 days); median time to onset to first
occurrence of febrile neutropenia was 77 days (range 3 – 304 days).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage 2b1dc6b51c4b3c30179ed34a9306b901719663e927e4ecdaac658f4649de49ac · Zeichen 15544–16657 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-147424 · Präparat HOS-099656
Thrombocytopenia
In the L-MIND study, incidence of thrombocytopenia was 31%. Incidence of Grade 3 or 4
thrombocytopenia was 17%. Median duration of any adverse reaction thrombocytopenia was 11 days
(range 1 – 470 days); median time to onset to first occurrence of thrombocytopenia was 71 days (range
1 – 358 days).
In the inMIND study, incidence of thrombocytopenia was 17.1% in the tafasitamab group
(tafasitamab, lenalidomide and rituximab) and 20.6% in the placebo group (lenalidomide and
rituximab). Incidence of Grade 3 or Grade 4 thrombocytopenia was 6.4% in the tafasitamab group and
9.8% in the placebo group. Median duration of thrombocytopenia was 16 days (range 2 – 434 days);
median time to onset to first occurrence of thrombocytopenia was 33 days (range 1 – 324 days).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage 6d056c1d5eeb452cd015aa186104fa83e7c2368913583ec6759bc6ec1c0c687b · Zeichen 16659–17441 im Abschnitt
Nebenwirkungen · Minjuvi
MINJUVI 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11–12
HOS-147425 · Präparat HOS-099656
11
Anaemia
In the L-MIND study, incidence of anaemia was 36%. Incidence of Grade 3 or 4 anaemia was 7%.
Median duration of any adverse reaction of anaemia was 15 days (range 1 – 535 days); median time to
onset to first occurrence of anaemia was 49 days (range 1 – 1129 days).
When patients in the L-MIND study were switched from tafasitamab and lenalidomide in the
combination therapy phase to tafasitamab alone in the extended monotherapy phase, the incidences of
haematological events decreased by at least 20% for neutropenia, thrombocytopenia and anaemia; no
incidences of febrile neutropenia were reported with tafasitamab monotherapy (see sections 4.2 and
4.4).
In the inMIND study, incidence of anaemia was 17.1% in the tafasitamab group (tafasitamab,
lenalidomide and rituximab) and 14.5% in the placebo group (lenalidomide and rituximab). Incidence
of Grade 3 or 4 anaemia was 6.4% in the tafasitamab group and 6.5% in the placebo group. Median
duration of any adverse reaction of anaemia was 23 days (range 1 – 432 days); median time to onset to
first occurrence of anaemia was 49 days (range 1 – 274 days).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T10:55:00Z · SHA-256 db2a7a79208ec69a20e38f53f43274347a2acea4998641e0c9491f94bc291602 · Passage 3283cbbdfd131198bbd5a31d2aaa176601be4cc81b9c027d96c96fcbad22cf23 · Zeichen 17506–18624 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.